Please contact us for more information or to learn if you are eligible to participate.
This is a multicenter, randomized, study to evaluate the safety, immunogenicity, and efficacy of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo. The primary objectives are to evaluate the safety and efficacy of the vaccine compared to placebo.
Dynio Honrubia, MD
Luis Cantu Jr.
National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC)
Type of Trial